Formula makers cannot use US government statement in trial over preterm baby illness
By Brendan Pierson
Oct 23 (Reuters) -Abbott ABT.N and Reckitt's RKT.L Mead Johnson will not be allowed to show jurors a statement by U.S. government agencies and a government-commissioned report to defend themselves against a lawsuit by a mother who says her son got a severe intestinal illness from the companies' baby formula for premature infants.
The ruling by Missouri Circuit Judge Michael Noble in St. Louis, Missouri, state court on Wednesday comes in the middle of a trial that began in late September and is expected to last five weeks. Noble said the statement and report were not new research and rejected the companies' argument that they should be allowed in court because they are "authoritative."
Plaintiff Elizabeth Whitfield says that her son, Kaine, developed necrotizing entercolitis (NEC) as a result of being fed the companies' formulas after he was born premature at less than 28 weeks, weighing just over 1,000 grams, or 2.2 pounds. The disease required Kaine to have surgery and left him with developmental delays, malnutrition and other health problems, Whitfield says.
Abbott declined to comment on Wednesday's ruling. Reckitt and a lawyer for Whitfield did not immediately respond to requests for comment.
Whitfield's case is one of close to 1,000 similar cases nationwide, and comes after two previous trials that resulted in verdicts of $60 million against Reckitt and $495 million against Abbott. Plaintiffs claim that the formula companies failed to warn that their products can cause NEC in babies weighing less than 1,500 grams, or about 3.3 pounds.
Both companies have said that their products do not cause NEC but rather that mother's milk or donated human milk protects against it, and that this protective effect has long been known to doctors and incorporated into hospital feeding practices.
To support that position, they sought to have their expert witnesses testify at the trial about a recent statement by the U.S. National Institute of Health (NIH), Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) that formula is "part of the standard of care" for preterm infants when milk is not available or insufficient, and that there is "no conclusive evidence that preterm infant formula causes NEC."
They also sought to introduce a report released last month by a working group of doctors and researchers convened by the NIH, which states that available evidence "supports the hypothesis that it is the absence of human milk - rather than the exposure to formula - that is associated with an increase in the risk of NEC."
Noble, however, ruled that there was no case law "directly on point for authoritativeness of a press release by a governmental regulatory body or a working group's report."
While neither document directly mentions the litigation, the working group was convened less than a month after the blockbuster $495 million verdict against Abbott. The verdicts have raised widespread alarm from doctors who fear that the lawsuits could jeopardize the formulas' availability or inappropriately influence medical decisions.
Abbott CEO Robert Ford told investors in a call earlier this month that it would be "very difficult for any company to remain on the market with these products" in the face of "indefinite liability." Reckitt in July said it was "considering options" for Mead Johnson, and CEO Kris Licht did not rule out a sale.
Unlike most of the NEC plaintiffs, Whitfield is suing not only the formula makers but also the hospital where her son was born, St. Louis Children's Hospital, for malpractice. The hospital has denied the claim.
The case is K.W. by and through Next Friend Elizabeth Whitfield v. St. Louis Children's Hospital et al, Missouri Circuit Court, 22nd Judicial Circuit, No. 2222-CC-06214.
For Whitfield: Tim Cronin of The Simon Law Firm
For Abbott: Jim Hurst of Kirkland & Ellis
For Mead Johnson: Phyllis Jones of Covington & Burling
For St. Louis Children's: Teresa Bartosiak of Bartosiak Makepeace
Read more:
Abbott, Reckitt face trial over premature baby formula amid alarm from doctors
Reckitt unit hit with $60 million verdict in Enfamil baby formula case in Illinois
Abbott must pay $495 million in premature infant formula trial, jury finds
Reckitt to offload homecare brands, consider nutrition options
(Reporting By Brendan Pierson in New York)
</body></html>
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
